Immunology Partnering Terms and Agreements -





Published: February 2014 | Pages: 1159

The Immunology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the immunology partnering deals and agreements entered into by the worlds leading healthcare companies.

 

The report provides a detailed understanding and analysis of how and why companies enter immunology partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors immunology technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

                                

This report contains over 1,000 links to online copies of actual immunology deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

The initial chapters of this report provide an orientation of immunology dealmaking and business activities. Chapter 1 provides an introduction to the report.

 

Chapter 2 provides an overview of the trends in immunology dealmaking since 2009 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

                             

Chapter 3 provides a review of the leading immunology deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of immunology deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 5 provides comprehensive access to all immunology deals since 2009 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

 

Chapter 6 provides a comprehensive directory of all immunology partnering deals signed and announced since 2009. The chapter is organized by specific immunology therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

In addition, a comprehensive appendix is provided with each report of all immunology partnering deals signed and announced since 2009. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in immunology partnering and dealmaking since 2009.

                                                  

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of immunology technologies and products.

Executive Summary 

  

Chapter 1 – Introduction 

  

Chapter 2 – Trends in immunology dealmaking 

 

2.1. Introduction

2.2. Immunology partnering over the years

2.3. Bigpharma immunology dealmaking activity

2.4. Bigpharma not active in immunology          

2.5. Immunology partnering by deal type           

2.6. Immunology partnering by industry sector

2.7. Immunology partnering by stage of development

2.8. Immunology partnering by technology type

2.9. Immunology partnering by immunology indication

2.10. Average deal terms for immunology

2.10.1 Immunology headline values

2.10.2 Immunology upfront payments

2.10.3 Immunology milestone payments

2.10.4 Immunology royalty rates

 

Chapter 3 – Leading immunology deals 

 

3.1. Introduction

3.2. Top immunology deals by value

3.3. Top immunology deals involving bigpharma

 

Chapter 4 – Bigpharma immunology deals 

 

4.1. Introduction

4.2. How to use bigpharma partnering deals

4.3. Bigpharma immunology partnering company profiles

Abbott

Allergan

Amgen

Aspen Pharmacare

Astellas

AstraZeneca

Baxter International

Bayer

Biogen Idec

Boehringer Ingelheim

Bristol-Myers Squibb

Celgene

CSL

Daiichi Sankyo

Dainippon Sumitomo

Eisai

Eli Lilly

Forest Laboratories

Gilead Sciences

GlaxoSmithKline

Grifols

Johnson & Johnson

Lundbeck

Merck & Co

Merck KGaA

Mitsubishi Tanabe

Novartis

Novo Nordisk

Pfizer

Purdue

Roche

Sanofi

Servier

Shionogi

Takeda

Teva   

Valeant

Watson

 

Chapter 5 – Immunology partnering contracts directory 

 

5.1. Introduction

5.2. By deal type

Asset purchase

Assignment

Bigpharma outlicensing

Co-development

Collaborative R&D

Co-market       

Contract service

Co-promotion   

Cross-licensing

Development   

Distribution      

Equity purchase           

Joint venture    

Licensing

Litigation

Loan

Manufacturing

Marketing

Option

Promotion

Research

Settlement

Sub-license

Supply

Termination

5.3. By stage of development

Discovery        

Formulation     

Marketed         

Phase I

Phase II           

Phase III          

Preclinical       

Regulatory       

5.4. By technology type

Antibodies       

Assays

Biological compounds  

Cell therapy

Devices           

Discovery tools

Drug delivery   

Enabling technology

Equipment       

Facilities          

Genomics        

In vitro models 

Natural product

Oligonucleotide

Orphan drug    

Packaging       

Peptides          

Processes       

Proteomics      

Recombinant DNA       

RNA therapeutics         

Screening        

Small molecules          

Stem cells       

Vaccines         

 

Chapter 6 – Immunology dealmaking by indication 

 

6.1. Introduction

6.2. Deals by therapeutic indication

Immunology

AIDS   

Allergy

Anaphylactic shock

Graft versus host disease

Inflammation

Systemic lupus erythematosus

Scleroderma

                                                     

Chapter 7 – Partnering resource center 

 

7.1. Online partnering   

7.2. Partnering events  

7.3. Further reading on dealmaking

 

Appendices 

 

Appendix 1 – Directory of immunology deals by company A-Z 2007-2012           

Appendix 2 – Directory of immunology deals by deal type 2007-2012

Appendix 3 – Directory of immunology deals by stage of development 2007-2012

Appendix 4 – Directory of immunology deals by technology type 2007-2012       

Appendix 5 – Deal type definitions                 

 

About Wildwood Ventures         

Current Partnering       

Current Agreements     

Recent titles from CurrentPartnering

Order Form – Reports

Order Form – Therapy Reports

 

Table of figures 

 

Figure 1: Immunology partnering since 2009     

Figure 2: Bigpharma – top 50 – immunology deals 2007 to 2012

Figure 3: Bigpharma immunology deal frequency – 2007 to 2012           

Figure 4: Inactive bigpharma in immunology 2007-2012 

Figure 5: Immunology partnering by deal type since 2009          

Figure 6: Immunology partnering by industry sector since 2009 

Figure 7: Immunology partnering by stage of development since 2009   

Figure 8: Immunology partnering by technology type since 2009

Figure 9: Immunology partnering by immunology target since 2009       

Figure 10: Immunology deals with a headline value       

Figure 11: Immunology deal headline value distribution, US$million – discovery stage

Figure 12: Immunology deal headline value distribution, US$million – preclinical stage

Figure 13: Immunology deal headline value distribution, US$million – phase I stage

Figure 14: Immunology deal headline value distribution, US$million – phase II stage

Figure 15: Immunology deal headline value distribution, US$million – phase III stage

Figure 16: Immunology deal headline value distribution, US$million – regulatory stage   

Figure 17: Immunology deal headline value distribution, US$million – marketed stage    

Figure 18: Summary median headline value by stage of development, 2007-2012           

Figure 19 Immunology deals with upfront payment values

Figure 20: Immunology deal upfront payment distribution, US$million – discovery stage

Figure 21: Immunology deal upfront payment distribution, US$million – preclinical stage

Figure 22: Immunology deal upfront payment distribution, US$million – phase I stage

Figure 23: Immunology deal upfront payment distribution, US$million – phase II stage

Figure 24: Immunology deal upfront payment distribution, US$million – phase III stage

Figure 25: Immunology deal upfront payment distribution, US$million – regulatory stage

Figure 26: Immunology deal upfront payment distribution, US$million – marketed stage

Figure 27: Summary median upfront payments by stage of development, 2007-2012

Figure 28: Immunology deals with milestone payments

Figure 29: Immunology deal milestone distribution, US$million – discovery stage

Figure 30: Immunology deal milestone distribution, US$million – preclinical stage

Figure 31: Immunology deal milestone distribution, US$million – phase I stage

Figure 32: Immunology deal milestone distribution, US$million – phase II stage

Figure 33: Immunology deal milestone distribution, US$million – phase III stage

Figure 34: Immunology deal milestone distribution, US$million – regulatory stage

Figure 35: Immunology deal milestone distribution, US$million – marketed stage

Figure 36: Immunology deals with royalty rates, %

Figure 37: Immunology deal royalty rate distribution, US$million – discovery stage

Figure 38: Immunology deal royalty rate distribution, US$million – preclinical stage

Figure 39: Immunology deal royalty rate distribution, US$million – phase I stage

Figure 40: Immunology deal royalty rate distribution, US$million – phase II stage

Figure 41: Immunology deal royalty rate distribution, US$million – phase III stage

Figure 42: Immunology deal royalty rate distribution, US$million – regulatory stage

Figure 44: Summary median royalty rate by stage of development, 2007-2012

Figure 45: Top immunology deals by value since 2009

Figure 46: Top immunology deals signed by bigpharma value since 2009

Figure 47: Online partnering resources